BioRestorative's BRTX-100 Gets FDA Nod for Cervical Disc Pain, CEO Outlines Growth Plans
BioRestorative Therapies, Inc. (BRTX) has received a significant boost with the FDA's IND clearance for BRTX-100 to treat chronic cervical discogenic pain. CEO Lance Alstodt discussed this and other developments in a wide-ranging interview, aired across multiple platforms worldwide.
The interview, broadcast on cable TV, streaming services like Roku, radio networks including Armed Forces Radio and iHeart Media, covered BioRestorative's recent milestones. BRTX-100, the company's lead cell therapy candidate, is already in Phase 2 trials for chronic lower back pain and has now received clearance for cervical discogenic pain.
Alstodt highlighted the company's expanding commercial opportunities. BioRestorative is exploring new areas such as its Metabolic Program, ThermoStem, which targets obesity and metabolic disorders. The company is also looking to expand its commercial offering to include more cell-based biologic aesthetic products, building on its existing BioCosmeceutical platform that reduces fine lines and wrinkles.
BioRestorative, a leader in regenerative medicine, continues to make strides in stem cell-based therapies. With the FDA's clearance for BRTX-100 and its expanding commercial pursuits, the company looks set to make significant strides in improving lives through innovative treatments.
